Gemini DRC A Multicenter, Open-label, Multiple Dose Study in Patients with Geographic Atrophy Secondary to Dry AMD to Evaluate the Safety, Tolerability, Pharmacodynamics, and Immunogenicity of Repeat Intravitreal Injections of GEM103
Research Grant
Administered By
Ophthalmology
Awarded By
Gemini Therapeutics
Start Date
August 17, 2020
End Date
August 31, 2022
Administered By
Ophthalmology
Awarded By
Gemini Therapeutics
Start Date
August 17, 2020
End Date
August 31, 2022